(Q77091149)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

review article

1 reference

title

Adjuvant post-operative therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

K Leiper

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

I London

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

J M Rhodes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 March 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

Bailliere's clinical gastroenterology

2 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

179-199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

Crohn's disease: maintenance of remission by diet

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Effect of cigarette smoking on the course of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Recurrence of Crohn's disease after primary excisional surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Enteral nutrition as primary therapy in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Treatment of Crohn's disease with an unrefined-carbohydrate, fibre-rich diet

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Medical management of chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

The prevention of Crohn's disease after surgery: metronidazole is a small but continuous medical advancement

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Colonic Crohn's disease and use of oral contraception.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Low dose steroids and clinical relapse in Crohn's disease: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Effect of cigarette smoking on recurrence of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Effect of oral contraceptive use on reoperation following surgery for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Cigarette smoking and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2898%2990092-6

7 January 2021

10.1016/S0950-3528(98)90092-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9704162%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference